{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:20:52Z","timestamp":1789791652259,"version":"4.0.1"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.81803583"],"award-info":[{"award-number":["No.81803583"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2019JJ50854"],"award-info":[{"award-number":["2019JJ50854"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2021JJ31074"],"award-info":[{"award-number":["2021JJ31074"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2023JJ30755"],"award-info":[{"award-number":["2023JJ30755"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Kidney transplantation recipients (KTRs) represent a vulnerable population for COVID-19 infection and severe disease. Nirmatrelvir-ritonavir has demonstrated efficacy in treating COVID-19 among KTRs, and interacts with tacrolimus leading to a precipitous increase in tacrolimus blood levels when co-administered, which may potentially result in toxicity. To explore a safe strategy for the combination of nirmatrelvir-ritonavir and tacrolimus, we established a new administration strategy to restore tacrolimus after the discontinuation of nirmatrelvir-ritonavir and conducted a real-world retrospective observational cohort study to evaluate its clinical efficacy. In the experimental group, tacrolimus was initiated at 20\u201325% of the baseline dose 48 hours after the discontinuation of nirmatrelvir-ritonavir, with daily increments of 20\u201325% until the baseline dose was restored. The patients who did not follow the experimental protocol were included in the control group. Results showed that withholding tacrolimus 12 hours before starting nirmatrelvir-ritonavir maintained tacrolimus blood levels above 83% of the baseline throughout the nirmatrelvir-ritonavir treatment period. Compared with the control group, the experimental group achieved target trough concentrations of tacrolimus more quickly and maintained a higher proportion within the therapeutic range (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.029), and had significantly lower rates of adverse events (\n                    <jats:italic>p\u2009=\u2009<\/jats:italic>\n                    0.002, OR\u2009=\u20090.308, 95%CI:0.136\u20130.695). This study provides a safe and effective pharmacological strategy for KTRs infected with COVID-19, allowing the safe co-administration of nirmatrelvir-ritonavir and tacrolimus.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0309875","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T13:38:22Z","timestamp":1748612302000},"page":"e0309875","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimized tacrolimus dosing strategy in kidney transplant recipients receiving nirmatrelvir-ritonavir for COVID-19"],"prefix":"10.1371","volume":"20","author":[{"given":"Han","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanbiao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rao","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hualin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6500-5820","authenticated-orcid":true,"given":"Gongbin","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"issue":"1","key":"pone.0309875.ref001","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41392-022-00997-x","article-title":"SARS-CoV-2 Omicron variant: recent progress and future perspectives","volume":"7","author":"Y Fan","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"17","key":"pone.0309875.ref002","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1001\/jama.2021.4385","article-title":"Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients","volume":"325","author":"BJ Boyarsky","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"pone.0309875.ref003","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/TP.0000000000003523","article-title":"COVID-19 and solid organ transplantation: a review articl","volume":"105","author":"Y Azzi","year":"2021","journal-title":"Transplantation"},{"issue":"1","key":"pone.0309875.ref004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/rmv.2149","article-title":"Transplantation in the era of the Covid-19 pandemic: how should transplant patients and programs be handled?","volume":"31","author":"MM NasrAllah","year":"2021","journal-title":"Rev Med Virol"},{"issue":"1","key":"pone.0309875.ref005","doi-asserted-by":"crossref","first-page":"100588","DOI":"10.1016\/j.trre.2020.100588","article-title":"COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis of current literature","volume":"35","author":"MA Raja","year":"2021","journal-title":"Transplant Rev (Orlando)"},{"issue":"6","key":"pone.0309875.ref006","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1097\/TP.0000000000003670","article-title":"Outcomes of COVID-19 in solid organ transplant recipients: a propensity-matched analysis of a large research network","volume":"105","author":"YB Hadi","year":"2021","journal-title":"Transplantation"},{"issue":"3","key":"pone.0309875.ref007","doi-asserted-by":"crossref","first-page":"100628","DOI":"10.1016\/j.trre.2021.100628","article-title":"The association between severe or death COVID-19 and solid organ transplantation: a systematic review and meta-analysis","volume":"35","author":"G Ao","year":"2021","journal-title":"Transplant Rev (Orlando)"},{"issue":"7","key":"pone.0309875.ref008","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1111\/ajt.16428","article-title":"Incidence and outcome of SARS-CoV-2 infection on solid organ transplantation recipients: a nationwide population-based study","volume":"21","author":"S Trapani","year":"2021","journal-title":"Am J Transplant"},{"issue":"10","key":"pone.0309875.ref009","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1111\/ajt.17098","article-title":"Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge","volume":"22","author":"C Radcliffe","year":"2022","journal-title":"Am J Transplant"},{"issue":"3","key":"pone.0309875.ref010","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciac443","article-title":"Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients","volume":"76","author":"R Najjar-Debbiny","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pone.0309875.ref011","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.therap.2022.03.005","article-title":"Management of drug-drug interactions with nirmatrelvir\/ritonavir in patients treated for Covid-19: guidelines from the French Society of Pharmacology and Therapeutics (SFPT)","volume":"77","author":"F Lemaitre","year":"2022","journal-title":"Therapie"},{"issue":"15","key":"pone.0309875.ref012","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"J Hammond","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0309875.ref013","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2174\/1389200219666180129151948","article-title":"Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation","volume":"19","author":"M Yu","year":"2018","journal-title":"Curr Drug Metab"},{"issue":"10","key":"pone.0309875.ref014","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation","volume":"43","author":"CE Staatz","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"pone.0309875.ref015","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14752","article-title":"Single-center experience with nirmatrelvir\/ritonavir in kidney transplant recipients on tacrolimus maintenance immunosuppression","volume":"36","author":"K Mecadon","year":"2022","journal-title":"Clin Transplant"},{"key":"pone.0309875.ref016","first-page":"1","article-title":"Drug-drug interaction of Nirmatrelvir\/ritonavir and tacrolimus: A potential risk disproportionality analysis of nephrotoxicity from COVID-19 reports in FAERS","author":"F Qin","year":"2023","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"pone.0309875.ref017","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.transproceed.2022.04.015","article-title":"Paxlovid (Nirmatelvir\/Ritonavir) and tacrolimus drug-drug interaction in a kidney transplant patient with SARS-2-CoV infection: a case report","volume":"54","author":"M Prikis","year":"2022","journal-title":"Transplant Proc"},{"issue":"7","key":"pone.0309875.ref018","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1111\/ajt.16955","article-title":"Nirmatrelvir\/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants","volume":"22","author":"NW Lange","year":"2022","journal-title":"Am J Transplant."},{"issue":"5","key":"pone.0309875.ref019","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/clpt.2011.164","article-title":"Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy","volume":"90","author":"S Katzenmaier","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"pone.0309875.ref020","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1016\/j.ekir.2022.08.026","article-title":"Safety, efficacy, and relapse of nirmatrelvir-ritonavir in kidney transplant recipients infected with SARS-CoV-2","volume":"7","author":"A Devresse","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"8","key":"pone.0309875.ref021","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40261-022-01180-4","article-title":"Paxlovid-tacrolimus drug-drug interaction in a 23-year-old female kidney transplant patient with COVID-19","volume":"42","author":"N Berar","year":"2022","journal-title":"Clin Drug Investig"},{"issue":"2","key":"pone.0309875.ref022","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14037","article-title":"Saving lives with nirmatrelvir\/ritonavir one transplant patient at a time","volume":"25","author":"KA Belden","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"4","key":"pone.0309875.ref023","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s00467-022-05712-0","article-title":"Elevated tacrolimus levels after treatment with nirmatrelvir\/ritonavir (Paxlovid) for COVID-19 infection in a child with a kidney transplant","volume":"38","author":"C Young","year":"2023","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"pone.0309875.ref024","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14807","article-title":"Prediction of tacrolimus and Wuzhi tablet pharmacokinetic interaction magnitude in renal transplant recipients","volume":"36","author":"P Chen","year":"2022","journal-title":"Clin Transplant"},{"issue":"5","key":"pone.0309875.ref025","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/ajt.13111","article-title":"Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir","volume":"15","author":"P Badri","year":"2015","journal-title":"Am J Transplant"},{"issue":"10","key":"pone.0309875.ref026","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1093\/jac\/dkaa253","article-title":"Stopping lopinavir\/ritonavir in COVID-19 patients: duration of the drug interacting effect","volume":"75","author":"F Stader","year":"2020","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"pone.0309875.ref027","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12964-022-00856-w","article-title":"A comprehensive review about immune responses and exhaustion during coronavirus disease (COVID-19)","volume":"20","author":"RN Mohammed","year":"2022","journal-title":"Cell Commun Signal"},{"issue":"1","key":"pone.0309875.ref028","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.it.2020.11.002","article-title":"T Cells: Warriors of SARS-CoV-2 Infection","volume":"42","author":"P de Candia","year":"2021","journal-title":"Trends Immunol"},{"issue":"7","key":"pone.0309875.ref029","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41591-021-01386-7","article-title":"CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer","volume":"27","author":"EM Bange","year":"2021","journal-title":"Nat Med"},{"issue":"17","key":"pone.0309875.ref030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176351","article-title":"Natural killer cell dysfunction and its role in COVID-19","volume":"21","author":"C van Eeden","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"6","key":"pone.0309875.ref031","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41423-020-0450-7","article-title":"NKG2A and COVID-19: another brick in the wall","volume":"17","author":"L Antonioli","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"pone.0309875.ref032","doi-asserted-by":"crossref","first-page":"580641","DOI":"10.3389\/fimmu.2020.580641","article-title":"Covid-19: perspectives on innate immune evasion","volume":"11","author":"N Taefehshokr","year":"2020","journal-title":"Front Immunol"},{"issue":"5","key":"pone.0309875.ref033","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","article-title":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients","volume":"17","author":"M Zheng","year":"2020","journal-title":"Cell Mol Immunol"},{"issue":"7888","key":"pone.0309875.ref034","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41586-021-04142-6","article-title":"Untimely TGF\u03b2 responses in COVID-19 limit antiviral functions of NK cells","volume":"600","author":"M Witkowski","year":"2021","journal-title":"Nature"},{"issue":"2","key":"pone.0309875.ref035","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/FTD.0000000000001014","article-title":"Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with nirmatrelvir\/ritonavir in patients with COVID-19","volume":"45","author":"F Lemaitre","year":"2023","journal-title":"Ther Drug Monit"},{"issue":"25","key":"pone.0309875.ref036","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMoa1408921","article-title":"An interferon-free antiviral regimen for HCV after liver transplantation","volume":"371","author":"PY Kwo","year":"2014","journal-title":"N Engl J Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0309875","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T13:38:30Z","timestamp":1748612310000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0309875"}},"subtitle":[],"editor":[{"given":"Vipula Rasanga","family":"Bataduwaarachchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0309875","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.08.22.24312416","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]}}}